Fuse Medical, Inc.

Fuse Medical, Inc. manufactures and distributes medical device implants in the United States. The company offers orthopedic implants, including internal and external fixation products for foot and ankle; upper and lower extremity plating and total joint reconstruction implants; soft tissue fixation and augmentation for sports medicine procedures; and full spinal implants for trauma, degenerative disc disease, and deformity indications. It also provides osteo-biologics and regenerative products, which include human allografts, tendons, synthetic skin and bone substitute materials, and regenerative tissues. The company serves hospitals, medical facilities, and sub-distributors. Fuse Medical, Inc. is based in Richardson, Texas.

Fuse Medical, Inc. trades as FZMD on OTC. The company is classified in Healthcare / Medical - Devices and reports in USD.

The current profile places the business in Medical - Devices. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $10.73M of revenue and $513,960 of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Fuse Medical, Inc. can be compared against peers such as Captiva Verde Wellness Corp., Metawells Oil & Gas Inc., PD-Rx Pharmaceuticals, Inc., Qscreen Ai Inc., REMSleep Holdings, Inc., Rennova Health, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $2.22M, beta of -0.52, and return on equity of +7.8%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

FZMD currently shows total debt of $2.22M and beta of -0.52. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.fusemedical.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.